Conditions DEA Policy Therapy 
Cannabis Law Report
OCTOBER 4, 2021
Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.
MJ Business Attorneys
JUNE 29, 2018
The FDA approved Epidiolex as a prescription drug to be used to treat two severe epileptic conditions, Lennox-Gastaut syndrome and Dravet syndrome. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
NOVEMBER 11, 2023
According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” Nonetheless, with the increasing legalization of medical cannabis, many veterans and interest groups have asked the government to change its policies. Yes, it has.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.
Veriheal
DECEMBER 27, 2022
Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. Researchers have taken a big step in understanding the connection between using psychedelics and feeling connected to nature in a study published in the journal Drug Science, Policy, and Law on Oct.
CannaMD
SEPTEMBER 10, 2020
Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.
Cannabis Law Report
AUGUST 23, 2021
FDA has not reviewed the manufacturing process of these unapproved CBD-containing drug products, so the manufacturing conditions of, or contaminant levels in, these products is unknown. He added that significant data is still needed to inform policy regarding use of consumer cannabis products.
Expert insights. Personalized for you.
52 
Let's personalize your content